Brief: Suven Life Sciences Announces Phase 3 Clinical Trial Of SUVN-502

Suven Life Sciences

16/08/2021 11:50

Aug 16 (Reuters) - Suven Life Sciences Ltd  SUVP.NS :
    * ANNOUNCES PHASE 3 CLINICAL TRIAL OF SUVN-502
    * SUVN-502 IS A 5-HT6 ANTAGONIST FOR TREATMENT OF AGITATION
AND
AGGRESSION IN ALZHEIMER'S TYPE DEMENTIAS
    * MULTI-CENTER STUDY COMPRISING ABOUT 387 PATIENTS LIKELY TO
BE
COMPLETED IN ABOUT 36 MONTHS
    * EXPECTS  ENROLLMENT OF PATIENTS FROM MIDDLE OF SEPTEMBER
2021
    * TOPLINE RESULT FROM STUDY EXPECTED BY END OF YEAR 2024

Further company coverage:  SUVP.NS 

 ((Reuters.Briefs@thomsonreuters.com;))